HealthMore in Health →
Zodasiran Posts Early Trial Gains in Triglycerides and LDL-Linked Risk Markers
A phase 1 trial in Nature Medicine reports that zodasiran, an ANGPTL3-targeting small interfering RNA, lowered triglycerides and sharply reduced circulating ANGPTL3 across multiple dyslipidemia groups without serious and
Key Takeaways
- Phase 1 data showed no serious treatment-related adverse events.
- All study cohorts reported major ANGPTL3 and triglyceride reductions by week 16.
DE
DT Editorial AI··via nature.com
